



PATENT
Customer No. 22,852
Attorney Docket No. 4853.0086-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

In re Application of:)
)
OGATA et al.) Group Art Unit: 1743
)
Application No.: 10/019,571) Examiner: Not yet assigned
)
Filed: December 31, 2001)
)
For: Therapeutic Agent for Diseases)
Caused by PTH or PTHrP)

Commissioner for Patents and Trademarks
Washington, DC 20231

Sir:

RECEIVED
MAR 28 2002
TC 1700

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the document listed on the attached PTO 1449. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage in an international application.

Applicants have provided a copy of the listed copending patent applications and the reference. As the original reference is in Japanese, Applicants have provided a translation. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1000 L Street, NW
Washington, DC 20005
202 462 4000
Fax 202 462 4400
www.finnegan.com

documents as prior art against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 26, 2002

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 L Street, NW
Washington, DC 20005
202 463 4000
Fax 202 463 4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	4853.0086-00	Appln. No.	10/019,571
Applicant	Ogata et al.		
Filing Date	December 31, 2001	Group:	1743

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	09/269,332		Sato et al.			March 25, 1999
	10/019,501		Ogata et al.			December 31, 2001
	10/019,785		Saito et al.			January 4, 2002

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Morimoto, Clinical Calcium 5(12):50-54 (1995) (translation).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce